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ABSTRACT
Background: Anderson-Fabry disease (AFD) is an inborn lysosomal enzymopathy 
resulting from the deficient or absent activity of the lysosomal exogalactohydrolase, 
α-galactosidase A. This deficiency, results in the altered metabolism of glycosphingolipids 
which leads to their accumulation in lysosomes, thus to cellular and vascular 
dysfunction. To date, numerous mutations (according to recent data more than 1000 
mutations) have been reported in the GLA intronic and exonic mutations. Traditionally, 
clinical manifestations are more severe in affected hemizygous males than in females. 
Nevertheless, recent studies have described severe organ dysfunction in women.
The aim of the study: This study reports clinical, biochemical, and molecular 
findings of the members of three Sicilian families. The clinical history of these 
patients highlights a remarkable interfamilial and intrafamilial phenotypic variability 
which characterizes Fabry disease relative to target organs and severity of clinical 
manifestations.
Discussion: Our findings, in agreement with previous data, report a little genotype-
phenotype correlation for the disease, suggesting that the wide phenotypic variability 
of Anderson-Fabry disease is not completely ascribable to different gene mutations 
but other factors and mechanisms seem to be involved in the pathogenesis and clinical 
expression of the disease. Moreover, this study emphasies the importance of pedigree 
analysis in the family of each proband for identifying other possibly affected relatives.
INTRODUCTION
Anderson-Fabry(AFD) disease, also known as Fabry 
disease, is a rare X-linked lysosomal storage disorder 
characterized by an altered glycosphingolipid metabolism 
because of a mutation in GLA gene encoding α-galactosidase 
A [1–4]. This enzymatic defect results in pathological 
accumulation of glycolipids, such as globotriaosylceramide 
(Gb3), in lysosomes of vascular endothelium and several cell 
types causing multi-organ involvement [5].
The classical phenotype of Fabry disease typically 
occurs in males in childhood or adolescence; it consists of 
gastrointestinal symptoms as diarrhoea, abdominal pain, 
fever, hypohidrosis, acroparesthesias, angiokeratomas, 
cornea verticillata. Over the years, affected subjects 
develop, progressive renal disease, cardiac and 
cerebrovascular complications leading to premature death 
in the fourth and fifth decades of life [6].
Some patients present later onset form of the 
disease, often exhibiting a single organ dysfunction.
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Approximately 70% of carrier women exhibit 
several symptoms of Fabry disease, even though 
their clinical manifestations are usually later in onset 
and milder than in affected males [7, 8]. However, 
some females may also present severe complications 
relative to its effect on men. The moderate and mild 
phenotypes and the wide variability which characterizes 
Fabry in females are partly explained by the process 
of lyonization or X-chromosome inactivation which 
occurs randomly. Because of random X-chromosome 
inactivation, enzymatic GLA assay may provide 
enzymatic levels within the normal range; thus, 
different from male patients, genetic testing is the only 
method which allows the detection of female carriers. 
Consequently, molecular analysis should be performed 
in women who are suspected to suffer from Fabry 
disease; moreover it is essential for a conclusive correct 
genetic counselling [9].
Previously, the estimated prevalence of Fabry 
disease was approximately one out of 40000 to one 
out of 117000 in male subjects [10]. These data have 
been recently reviewed; in fact, newborn screening 
programs suggest an unexpectedly elevated rate of 
GLA mutations causing the disease [11]. Moreover, the 
diffuse employment of genetic testing among patients 
with mild, late-onset clinical manifestations or doubtful 
symptomatology has allowed detecting numerous novel 
mutations over the past few years [12]. The role of intronic 
mutations and polymorphisms of a single nucleotide are 
yet to be well defined. However, they recently appear to 
contribute to the extreme clinical variability and severity 
of the disease.
Numerous studies have demonstrated the molecular 
heterogeneity of Fabry disease. To date, researchers have 
identified more than one thousand mutations, a large part 
of them are private mutations that are to say specific to a 
particular family.
The study of several families reveals that despite a 
single mutation, the clinical expression of the disease may 
be significantly heterogeneous, as reported in the renal 
involvement of a large Slovenian family [13].
A considerable variability exists in phenotypic 
expression of the disease and organ involvement, 
suggesting that in addition to genotype, other factors 
may contribute and influence the clinical expression of 
this lysosomal disorder, such as environmental factors, 
polymorphisms of other genes (interleukin 6, nitric oxide 
synthase), modifiers of lysosomal pH, intra-gene factors, 
and epigenetics. In the light of these and other unknown 
phenomena, the correlation between genotype and 
phenotype is not so close thus the result is unreliable [14].
We report the clinical, biochemical, molecular 
study of three Sicilian families (see Figure 1 and Table 
1); our results confirm the wide phenotypic variability 
of Anderson-Fabry disease among members of a given 
family with a specific gene mutation and possibly may 
evoke further debates about this interesting topic.
RESULTS
After obtaining informed consents, we performed 
the clinical evaluation, enzyme assay for measuring GLA 
activity, genetic testing in 12 members of three Sicilian 
families.
Figure 1: Family trees and pedigree symbols of three sicilian families with Anderson-Fabry disease.
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Family 1: polymorphism -10 C>T; IVS2-
76_80del5; IVS4-16 A>G; IVS6-22 C>T
In this family, the proband (case II/1), a 59-year-
old woman, presented cerebrovascular manifestations of 
Fabry disease. She had occasional detection at brain MRI 
of extensive, symmetric white matter hyperintensities 
(WMHLs) with relative sparing of subcortical white 
matter. MRI was performed because she often complained 
of a diffuse headache associated with tinnitus and 
dizziness After administration of mini-mental state 
examination (MMSE) she did not show any objective 
evidence of cognitive impairment. She also suffered from 
early-onset hypoacusis and acroparesthesias, since the 
age of 35. In the light of brain MRI findings, the absence 
of cerebrovascular risk factors, after the exclusion of 
autoimmune, thrombophilic disorders Anderson-Fabry 
disease was suspected. Her alpha-galactosidase A 
activity was 3.7 nmol/ml/h, which is compatible with a 
heterozygote female subject or healthy subject.
The proband’s son (CASE III/1), a 30-year-old male, 
has suffered from acroparesthesias and hyperhidrosis 
since adolescence. During childhood, he complained 
gastrointestinal symptoms (recurrent nausea, abdominal 
pain and diarrhoea). A mild impaired renal function has 
been detected at the age of 29 years old (GFR=65 ml/
min). Plasma α-Gal A activity was significantly decreased, 
a common typical value for hemizygous men with 
Anderson-Fabry disease.
Another member of this family group, a 41-year-
old female (case III/3), suffered from a paucisymptomatic 
variant of AFD characterised by acroparesthesias, 
Table 1: Plasma α-galactosidase A activity, GLA mutation, clinical manifestations in three Sicilian families
Organ involvement and symptoms
Age/ sex α-Gal GLA mutation Skin Eye Pain Gastrointestinal Ear Heart Brain Kidney
Pedigree 1
59/F 3.7
-10 C>T; IVS2-76_80del5; 
IVS4-16 A>G; IVS6-22 C>T
(Heterozygote)
− − + − + − + −
30/M 1
-10 C>T; IVS2-76_80del5; 
IVS4-16 A>G; IVS6-22 C>T
(Hemizygote)
− − + + − − − +
41/F 4.1
-10 C>T; IVS2-76_80del5; 
IVS4-16 A>G; IVS6-22 C>T
(Heterozygote)
− − + − + − − −
9/M 1.65
-10 C>T; IVS2-76_80del5; 
IVS4-16 A>G; IVS6-22 C>T
(Hemizygote)
− − + + − − − −
Pedigree 2
58/F 3.3 c.614delC(Heterozygote) − − + − − + + −
28/M 0 c.614delC(Heterozygote) + + +++ − − + − +
36/F 3.4 c.547G>A p.G183S(Hemizygote) + − ++ ++ − − − ++
34/F 3.3 c.547G>A p.G183S(Heterozygote) − − + − − − − +
Pedigree 3
55/M 0.4 c.547G>A p.G183S(Hemizygote) − − − − +++ +++ − ++
18/F 3 c.547G>A p.G183S(Heterozygote) − − ++ − − − − ++
20/F 3.6 c.547G>A p.G183S (Heterozygote) − − − − − − − −
58/F 3.7 c.547G>A p.G183S (Heterozygote) − − − − − − − +++
+, mild; ++ moderate; +++, severe
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hyperhidrosis, exercise and heat intolerance. She has 
reported episodic painful crisis characterized by burning 
sensation primarily in the extremities and radiating 
inwards to the limbs, for ten years. However, magnetic 
resonance imaging of her spinal cord showed multiple 
cervical herniations that could in part clarify her 
neuropathy. Also, she presented bilateral hypoacusis and 
central vestibular abnormalities of probable vascular 
origin. No neuroimaging findings are suggestive of 
cerebral involvement from Fabry disease. A-Gal A activity 
was 4.1 nmol/ml/h. To date, enzymatic replacement 
therapy has not been started yet.
The proband’s grandson (case IV/1), a 10-year-
old child, presented a classic phenotype of AFD with 
early onset of symptoms. He has mainly suffered 
from gastrointestinal involvement (chronic recurrent 
abdominal pain) and peripheral neuropathy since the age 
of 4. Gastrointestinal involvement consisted of recurrent 
episodes of diffuse abdominal pain primarily in the meso-
hypogastric region, postprandial bloating, early satiety and 
later, chronic diarrhoea, trouble gaining weight. Also, he 
presented typical Fabry crises. Plasma enzyme activity 
was typically decreased (1.65 nmol/ml/h). He started 
enzymatic replacement treatment at the age of six years.
Molecular genetics revealed the same polymorphism 
for each component member of this family: -10 C>T; 
IVS2-76_80del5; IVS4-16 A>G; IVS6-22 C>T [15].
Family 2: mutation c.614delC
The proband, a 57-year-old female, has complained 
mainly of central and peripheral neurological involvement 
with recurrent ischemic strokes, since the age of 45; 
and acroparesthesias, sensitive polyneuropathy since 
the age of 30. Her brothers (case II/1 and case II/5), 
presented respectively an ischemic stroke at the age of 
40 and a cardiac death for myocardial infarction. Her 
mother underwent dialysis for end-stage renal disease. 
Moreover, the proband suffered from cardiovascular 
disease (coronary artery disease, valvulopathy, peripheral 
vasculopathy) in the absence of neither cardiovascular risk 
factors nor autoimmune, thrombophilic disorders.
Her son (case III/3), a 29-year-old man has 
developed the classic phenotype of Fabry disease. He had 
typical features of AFD with systemic organ involvement 
consisting of small-fiber peripheral neuropathy, autonomic 
dysfunction, skin lesions (multiple angiokeratomas), 
ocular manifestations (cornea verticillata), mild renal 
impairment (GFR: 71 ml/min), cardiac involvement 
(moderate left ventricular hypertrophy). The patient had 
the lowest plasma alpha-galactosidase A activity among 
our patients (0 nmol/h/ml) (15).
In this family, other two members (case III/4 and 
case III/5) had mild-moderate clinical manifestations. 
The first was a 36-year-old female who has complained 
gastrointestinal symptoms, as cramp-like abdominal 
pain and diarrhoea since adolescence. Also, she 
presented angiokeratomas affecting the genital region, 
acroparesthesias, diffuse arthralgias. Finally, kidney 
involvement was detected, urinary protein excretion 
was 250 mg/24h. After this additional renal finding, 
ERT was started. Her sister, 37 years (case III/5) had a 
late onset milder form of the disease characterised by 
acroparesthesias and later mild proteinuria. [data not yet 
published].
Genetic DNA sequence analysis detected a point 
mutation c.614delC [15].
Molecular genetics of other three young members 
of the family 2 (cases IV/1, case IV/2, case IV/3) did 
not reveal any mutation in detecting the polymorphism: 
-12G>A;IVS4+68 A>G; IVS6-22C>T.
Family 3: mutation c.547G>A
This family consisted of 4 members suffered from 
Fabry disease, with the same mutation responsible for 
clinical manifestations.
The proband (case II/1), a 55-year-old man was 
a patient with the cardiac variant of Anderson-Fabry 
disease. He had concentric left ventricular hypertrophy 
(LVH), associated with thickening of the mitral valve and 
a shortened PR interval. Echocardiographic study showed 
a mild reduction of ejection fraction. Early symptoms 
were angina on effort and exertional dyspnea. His exercise 
stress test was positive for myocardial ischemia but 
coronary angiography ruled out significant stenosis. In 
addition, an extracardiac hallmark of AFD was a chronic 
renal disease (stage 3). His younger sister (case II/2) had 
hypertrophic cardiomyopathy. His older sister (case II/3) 
was affected by end stage renal disease; cardiac evaluation 
did not show signs of cardiovascular involvement.
The proband’s youngest daughter (case III/1), a 
17-year-old adolescent, presented with proteinuria (the 
first measurement of daily urinary protein excretion was 
250 mg/24h) and mildly reduced kidney function (GFR: 
73 ml/min, CKD-EPI). The only extra-renal features were 
acroparesthesias since the age of 12. The concentration 
of the biomarker lyso-Gb3 was increased to 7,5 ng/ml 
(reference ≤1,7 ng/ml); she has undergone ERT for two 
years. Case III/2 a 20-year-old female did not complain of 
symptoms and/or signs which may be suggestive of Fabry 
disease.
The mutation was detected in exon 3 of the GLA 
gene: c.547G>A.
Enzyme activity
In family 1, the two hemizygous subjects (case III/1, 
case IV/1) had a decrease in plasma, α-galactosidase A 
activity to 1 nmol/ml/h and 1,65 nmol/ml/ml, respectively. 
Enzyme activity was normal in the heterozygous female 
subjects: the proband’s plasma enzymatic activity was 3,7 
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nmol/ml/h, case III/3 showed a normal value of 4,1 nmol/
ml/h.
In family 2, plasma α-galactosidase A activity was 
significantly reduced in subject III-3, effectively its value 
was equal to 0 nmol/ml/h. Enzyme activity was within the 
normal range in proband II-2, subject III-5, subject III-4 
who were heterozygous (>3 nmol/ml/h).
The hemizygous patient of family 3 had a relevant 
alpha galactosidase A deficiency in plasma 0,4 nmol/ml/h, 
compatible with the affected male with Fabry disease. The 
heterozygous subjects showed normal values of alpha-
galactosidase A activity.
Analysis of lyso-GB3 concentrations was performed 
in some patients as case III/1 of family 3. She had 
increased levels of Lyso-GB3 (7,8 ng/ml, reference <1,8 
ng/ml).
Genetic analysis
In this study, 4 hemizygotes, including 1 proband 
and 3 newly detected hemizygotes, and 8 heterozygotes 
were diagnosed by gene analysis.
Family 1 showed these sequence alterations: −10 
C N T; IVS2-76_80del5; IVS4-16 A N G; IVS6-22 C>T, 
corresponding to genetic polymorphism identified by 
sequencing of the GLA gene. This genetic polymorphism 
has been detected in Fabry patients according to literature 
data. Recent studies have described this intronic haplotype 
in asymptomatic and paucisymptomatic variants of Fabry 
disease and in patients with small fibre neuropathy of 
unknown etiology [18, 19].
However, to date, no conclusive data exist regarding 
the pathogenic role of this complex intronic haplotype in 
Fabry disease.
Family 2 presented a point mutation, exactly a 
deletion of a single nucleotide (cytosine) in exon 4 of 
the GLA gene causing a frameshift mutation: c.614delC. 
Only the 29 year-old subject was hemizygous, whereas 
heterozygosity was detected in the proband a 57 year-
old woman, and in two female subjects aged 36 and 38, 
respectively.
The third family showed a deletion in exon 3 of the 
GLA gene (c.547G>A) resulting in a glycine to serine 
substitution at codon 183 (p.G183S). This mutation has 
previously been described as disease causing by Shabber 
et al [20]. The proband was the only hemizygous of this 
family. Heterozygosity was reported in 4 subjects of this 
group.
DISCUSSION
Fabry disease is characterized by an evident 
phenotypic variability. A considerable variability exists 
in the severity of disease and organ complications even 
between members of the same family; however the 
relationship between clinical manifestations, biochemical 
abnormalities, genetic mutations has not been clearly 
established. Some authors such as Vedder have not 
well defined a correlation between plasma and urinary 
Gb3 concentrations and most of the clinical signs and 
symptoms such as microalbuminuria, pain, and hearing 
loss [25].
Some specific mutations seem to be related to 
certain phenotypes with a predominantly single organ 
involvement, both cardiac variant, and cerebrovascular 
variant have been described. These forms are usually 
associated with a late onset phenotype [26, 27, 28].
Our results show a wide interfamilial and 
intrafamilial variability in the phenotypic expression 
of AFD, as regards both the target organs and disease 
severity. The great heterogeneity in disease expression is 
stressed by differences in most of the symptoms in family 
members carrying the same mutations.
Plasma α-galactosidas A activity and gene analyses 
were performed in all 13 members of three families that 
have come to our attention; four hemizygous and nine 
heterozygous were recognised.
Family 1, consisting of 4 members, is associated 
with polymorphism -10 C>T; IVS2-76_80del5; IVS4-16 
A>G; IVS6-22 C>T that was detected in AFD patients 
according to literature source. The significance of this 
haplotype in Fabry pathogenesis is still unknown, 
however, it is likely suggestive of AFD. In this first 
pedigree, a decrease in enzymatic activity was observed 
in two male patients; instead, the other members’ values 
were within the normal range [20, 23, 24].
The hemizygous subject and 3 heterozygotes from 
the second pedigree had a deletion of a single nucleotide in 
exon 4 leading to a frameshift mutation [21]. The proband 
and her two daughters had normal levels of plasma α-Gal 
A activity, whereas the hemizygous patient’s enzyme 
activity was found to be 0 nmol/ml/h.
Finally, family 3 consisted of 5 members (one man 
and four women, aged 18 to 59 years) with a mutation 
in exon 3 causing a Gly183Ser substitution [22]. The 
proband had a decrease in α-Gal A activity, whereas 4 
heterozygous female subjects had normal values.
Gene analysis is crucial for an accurate diagnosis 
because plasma alpha-galactosidase A activity was 
normal in most of the heterozygotes. Also, clinical and 
instrumental evaluation of patients is important for a 
more accurate diagnostic assessment. This consideration 
is relevant especially now that enzyme replacement 
treatment is available for this metabolic disorder that was 
incurable until about fifteen years ago [29].
All hemizygous patients among the three families, 
except the proband of family 3, who suffers from a typical 
cardiac variant of the disease, suffered from small fiber 
neuropathy, hypohidrosis, heat/exercise intolerance, 
gastrointestinal symptoms and two of them presented a 
classical phenotype of the disease ((case IV/1 in family 
1 and case III/3 in family 2). With regards to cardiac 
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variant, it should be noted that epidemiological studies 
have reported a prevalence of Fabry cardiomyopathy from 
1 to 12% among middle-aged patients with unexplained 
cardiac hypertrophy, thus it is advisable to screen these 
subjects for α-galactosidase A deficiency, and equally, 
patients suffering from known Fabry disease should be 
screened at an early stage for cardiac involvement, since 
treatment may not be effective once cardiac fibrosis has 
occurred [30].
Middle aged women of our studied families 
experienced predominantly cerebrovascular complications 
of AFD, whereas younger females have acroparesthesias 
that they have complained since adolescence, heat or 
cold intolerance, persistent non-specific gastrointestinal 
symptoms, and incipient kidney injury as manifested by 
new-onset proteinuria; the latter has justified the initiation 
of enzyme replacement treatment for three of them (case 
III/4, case III/5 of family 2, case III/1 of family 3). Only 
one heterozygous woman (case III/4 of family 2) had skin 
lesions (angiokeratomas).(see Table 1).
In each family, there was no correlation between 
the type of mutation found in α-GAL A gene and Fabry 
phenotype.
Medical history of these families, just as other 
pedigrees, highlights a wide phenotypic variability 
characterising Fabry disease in terms of organ involvement 
and disease severity, showing how a given mutation could 
express several phenotypes. It is well-known that Fabry 
disease is characterized by a poor phenotype-genotype 
correlation, thus a given mutation in a family may be 
responsible for different phenotypes.
Classically affected males experience first symptoms 
in infancy or adolescence (most of them complain of 
hypohidrosis, heat and cold intolerance, gastrointestinal 
symptoms, angiokeratoma) and have a more severe 
manifestation of the disease than heterozygous women, 
that are often asymptomatic according to Lyon's hypothesis 
of random inactivation of the X Chromosome [31] which 
partially explains less severe manifestations and wider 
variability in women. Moreover, literature reports many 
patients with only late involvement of one or two organs; 
these variants are usually associated with mutations that 
cause limited residual enzyme activity [4, 14].
On the basis of the current pathogenic hypothesis, it 
may be difficult to explain the lack of symptoms in patients 
with low enzyme activity. In this regard, Cammarata et al. 
[3], reported the case of two male members of the same 
family that showed the exonic mutation M51I; although 
their enzymatic activity was zero, they presented different 
clinical phenotypes. The eldest was asymptomatic, the 
youngest showed severe clinical manifestations; the 
current pathogenetic hypothesis does not clarify the poor 
symptomatology in the eldest hemizygous patient with 
absent enzyme activity. It is likely that the penetrance 
of different mutations is influenced by other variables 
(genetic, epigenetic or environmental factors) [4].
Recent studies report that heterozygous females 
may not be only mere carriers but women may experience 
serious clinical manifestations and irreversible organ 
damage. The extreme phenotypic variability does not seem 
entirely attributable to the numerous described mutations 
of GLA gene. Some authors have described mutations that 
were detected in patients with mild form and later also 
identified in severe cases [32].
Bono et al. have recently described mild or 
asymptomatic variants with residual enzymatic 
activity. The authors identified polymorphisms in 
the promoter region of the GLA gene in 12% of their 
analyzed subjects, and of these, 99% showed several 
simultaneous polymorphisms throughout the entire 
sequence; in particular they detected simultaneously 
two polymorphisms the -10 c>t, IVS2-76_80 del5, 
IVS4-16 A>G, IVS6-22C>T, which is identical to the 
polymorphism identified in our family 1, and -12 g>a, 
IVS4+68 A>G, IVS6-22C>T polymorphisms in 8.9% 
and 3.7% of the subjects; however the significance of 
this haplotype in the pathogenesis of Fabry disease 
remains still unknown. Also, other authors identified the 
first haplotype in patients with small fibre neuropathy of 
unknown etiology [23, 24].
Such examples and others suggest the existence 
of additional factors that impact on the phenotype of 
the disease (I.e.modifier genes, enviromental factors). 
In this regard, some hypotheses have been suggested: as 
the presence of residual enzyme activity in patients with 
classic form [4]; different levels of enzyme synthesis; 
different catalytic activity of the enzyme; the influence 
of environmental factors and not yet well-known genetic 
factors. To date, this appears an interesting and suggestive 
issue to continue to analyse [33]. Also, epigenetic 
mechanisms of gene regulation influence the penetrance of 
different disease-causing mutations. The latter hypothesis 
suggests that chromatin alterations of specific single 
nucleotide polymorphisms represent a platform that allows 
them to influence the phenotype. Chromatin variation is 
associated with distinct single nucleotide polymorphisms 
suggesting that the variation may serve as a platform to 
enable these SNPs often found in non-coding regions of 
DNA to influence phenotype; no study to our knowledge 
has yet assessed the role of these mechanisms in SNP 
associated with Fabry disease or other lysosomal disorders 
[14, 34–38].
Spence et al [38]. showed that there was a 
considerable variation in the clinical expression of the 
disease suggesting the presence of other interacting 
factors that may influence phenotype. Hamers et al [39]. 
suggested that clinical variability may be caused by other 
genes and/or environmental factors. A previous study by 
Beyer et al reported that two brothers with Fabry disease 
presented differences in severity of cardiovascular and 
renal symptoms [39–41].
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Lukas et al [36]. have highlighted and reaffirmed 
that to date a decrease in enzyme activity is the most 
relevant factor influencing the phenotype and its severity. 
However, the importance of modifier genes and epigenetic 
factor on clinical manifestations requires further 
researches to be confirmed.
Verovnik et al. have reported a significant 
variability in organ involvement in a Slovenian family 
with Fabry disease highlighting how a single specific 
mutation (N272S) may be responsible for heterogeneous 
deterioration of renal function; despite this mutation 
caused classical Fabry disease they described a wide 
variability of phenotypes among the seven hemizygotes 
of that family in particular, relative to renal disease [13].
No study has currently clarified whether the above 
mentioned processes individually or together explain 
the wide phenotypic variability and the different organ 
damage associated with Fabry disease and other lysosomal 
storage diseases. The role of intronic mutations and single 
nucleotide polymorphisms still has to be clarified. It 
has been shown that aberrant splicing of the messenger 
is the cause of at least 15% of human genetic diseases, 
highlighting the importance of studying intronic regions 
of the gene, too [42]. Since non-coding regions are not 
routinely evaluated, the occurrence of intronic-disease 
causing alterations should induce to analyse them when 
sequencing the GLA gene and to perform in these subjects 
further clinical and instrumental evaluation.
It is desirable that the GLA gene sequencing should 
be performed including routinely non-coding regions so 
as to identify possible disease-causing intronic lesions; 
thus, subjects that are affected from these polymorphisms 
should be undergone clinical and instrumental evaluation.
Patient follow-up will help us to better understand 
the role of intronic mutations on clinical manifestations 
of the disease. It is essential to establish a diagnostic 
process which is based on suggestive symptomatology 
and the presence of a classical GLA mutation, but this 
consideration is not possible for all phenotypes and 
genotypes of a patient with suspected Fabry disease thus 
in this circumstance a strict, careful clinical evaluation is 
required before starting ERT. For subjects with intronic 
mutations or single type polymorphism, avoiding in 
principle enzyme replacement treatment should not be 
recommended because it may lead to problems with the 
eventual progression of the disease especially in males but 
event in women and milder variants [15].
It is relevant the knowledge of the mechanism by 
which a mutation causes an altered function of the enzyme 
because numerous mutations are potential targets for 
alternative therapeutic strategy different from enzymatic 
replacement treatment, as pharmacological chaperone 
therapy [12].
Our results and other numerous case studies display 
a noteworthy intrafamilial and interfamilial clinical 
variability in terms of organ involvement and sometimes 
in terms of severity of the disease.
Our findings support previous observations 
highlighting the difficulties encountered by physicians in 
making a correct prognosis especially for young patients 
in reference to their family history.
In view of this, it becomes important the 
identification of biomarkers in order to establish the 
severity of disease and to monitor the effect of substitute 
treatment. To date, no markers are available in order to 
detect patients with increased risk of early complications. 
It is thus important recognising early signs and symptoms, 
bioumoral alterations so it would be possible to start early 
enzyme replacement therapy.
However, lyso Gb3 has been assuming a 
considerable role since it has been reported that its levels 
correlate with the severity and progression of the disease 
and they seem to be modified by enzyme replacement 
therapy [43, 44].
Further studies will clarify the pathogenesis of 
Fabry variability in order to improve the diagnostic and 
prognostic accuracy in Fabry disease. In addition, the 
study of large families may allow the identification of 
interacting factors influencing clinical expression and that 
may acquire a relevant value in order to decide the best 
time to start treatment.
MATERIALS AND METHODS
Measurement of enzyme activity: alpha-
galactosidase A, activity was measured by Dried Blood 
Filter Paper (DBFP) in all family members.
Refrigerated K-EDTA whole blood samples, arrived 
at our laboratory (max 24 hrs) from different hospitals via 
a prepaid shipping agency (TNT). Samples were listed and 
spotted for biochemical and genetic analysis. Microdisk (6 
mm diameter) was prepared from 9cm Whatman No. 113 
fast flow/coarse filter disk paper by using a common hole 
punched for documents. Whole blood of 5.5 μl is dispensed 
onto microdisk, using a Drummond positive pressure 
pipette. The disks were dried for two hours covered 
with a brief easy membrane (sigma MW08253). Ten 
disks of the same sample were put down in a horizontal 
line of the dark multiwell plate, with each letter on the 
microplate identifying a different sample. Samples were 
analysed in duplicate against a blank containing the spot 
and, in order, 250 μl of ethylendiammine 0.1 M pH 11.4 
and 70 μl of assay mix (below). To assess the specificity 
of the enzymatic reaction 3 μl of alphagalactosidase A, 
inhibitor (deoxygalactonojirimycin-hydrochloride (Sigma 
D9641)) was added onto two DBFP (these samples were 
incubated for 1 hr with assay mix). Finally, 70 μl of assay 
mix was added to each well with a multichannel pipette. 
The dark plate was covered with Breathe-easy membrane 
and incubated in a rotating shaker (37°C—300 rpm). 
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The kinetics of the reaction was measured at intervals of 
1 hr, 2 hrs and 3 hrs and was stopped by using 250 μl 
of ethylendiammine 0.1 M pH 11.4. The kinetics assay 
was carried out in a 384-well plate format using 1 nM 
enzyme with varying concentrations of substrate. Initially, 
10 μl/well, of the varying concentrations of the substrate 
was added to the plate. The reaction was initiated by the 
addition of 20 μl/well of enzyme solution. The 4MU-
α -Gala stock solution was serially diluted 1:1.5 to give 
eight concentrations. The final concentrations of the 
substrate used in the assay were 500, 333, 222, 148, 98.8, 
65.8, 43.9, and 29.3 μmol/L. Stop solution of 30 μl/well 
was added after 2, 4, 6, 8, 10, and 12 minute incubation 
times at RT. A quantitative research graph of the free 
fluorophore, 4-methylumbelliferone (4MU), in the same 
volume of assay buffer and stop solution was generated 
for calculating the enzyme product. The plate was read 
in the ViewLux plate reader at an emission wave-length 
of 440 nm and an excitation wave-length of 365 nm. In 
order to determine the type of inhibition and the inhibition 
constant of lansoprazole, five enzyme kinetics plots were 
generated in the presence of 80, 40, 20, 10, and 0 μmol/L 
of the inhibitor.
Reaction mix
Reaction mix was prepared in citrate, phosphate 
buffer (CPB) 0.15 M pH 4.5 (P4809-50 TAB Sigma, a tab 
dissolved in 33 mL H2O to obtain the wanted molarity). 
4-Methylumbelliferyla-D-galactopyranoside 5mM (Sigma 
M763) strained by 0.45nm syringe filter, and N-acetyl-
Dgalactosamine (Sigma A2795) 0.25 M, were mixed in 
a ratio of 2.5:1. Seventy microliters of this mixture was 
used for each well.
α-Galactosidase A inhibitor A
2 mg/mL of deoxygalactonojirimycin-hydrochloride 
(Sigma D9641) was prepared in distilled water. Prepared 
solution was then diluted in a ratio of 1:3 with CPB (citrate 
phosphate buffer). Using 3 μl of the prepared dilution, the 
final concentration in the assay was 1.3 × 10−7 M [16–18].
Alpha-galactosidase A activity
The values of enzyme activity obtained with Dried 
Blood Filter Paper (DBFP) range from 0 to 14 nmol/h/
mL. In brief, a 3.2-mm disk was punched and incubated 
at pH 4.4 and at 37°C with 4-methyl-umbelliferyl-
alpha-galactopyranoside as a substrate and N-acetyl-D-
galactosamine as an inhibitor for alpha-galactosidase B. 
Enzymatic activities measured on a Thermo Life Science 
fluorometer (Thermo Electron Corporation, Waltham, 
MA, USA) were expressed as nanomoles of substrate 
hydrolyzed per mL of blood per hour. Reference values 
for alpha-galactosidase activity are: males: N or =1.2 
nmol/mL/h; females: N or =2.8 nmol/mL/h [19]. Typical 
values for h hemizygous Fabry patients range from zero to 
1.5 nmol/hr/mL, while, healthy female and male subjects 
range from 3 to 14 nmol/h/ml).
Gene analysis: Direct sequencing of α-GAL A gene 
was conducted in all family members. DNA was extracted 
from whole blood. Peripheral blood was collected, using 
EDTA as an anticoagulant, from patients with clinical 
manifestations related to FD symptomatology. Genetic 
analysis was performed by high resolution melting 
(HRM) analysis on DNA samples, isolated from whole 
blood, using the Light Cycler 480 system. PCR products 
presenting melting curves in different positions or shapes 
from those of the wild-type control were sequenced to 
identify the suspected mutations.
Additional molecular genetics
To demonstrate intronic alterations, we applied 
the mismatch discover method known as HRM (high 
resolution melting) to identify human single nucleotide 
polymorphisms or mutations in GLA gene. For nuclease 
digestion, we performed one step of hybridization between 
wt and target DNA. Nuclease digestion required the 
addition of specific mismatch restriction enzyme called 
surveyor nuclease. Finally, polyacrylamide gel analysis 
was performed as protocols. We used high resolution 
melting (HRM) analysis for the rapid and sensitive 
detection of mutations in clinical samples. HRM assays 
were performed on the LightCycler® 480 Real-Time PCR 
System (Roche Diagnostics), analysed with the software 
Gene-Scanning Software Version 1.2 (Roche Diagnostics). 
CEL I and ENDO-1 endonucleases were used and primer 
sets were designed to cover the 7 exons and most common 
intronic mutation (10 C N T; IVS2- 76_80del5; IVS4-16 
A N G; IVS6-22 C N TVS4 + 919G N A) of GLA gene.
The concentration of the biomarker lyso-Gb3 in 
dried blood spot was measured using HPLC and tandem 
mass spectrometry.
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